S&P 500   3,351.28 (+0.06%)
DOW   27,433.48 (+0.17%)
QQQ   271.47 (-1.15%)
AAPL   444.45 (-2.45%)
MSFT   212.48 (-1.79%)
FB   268.44 (+1.19%)
GOOGL   1,498.37 (-0.44%)
AMZN   3,167.46 (-1.78%)
NVDA   447.98 (-1.20%)
CGC   16.63 (-5.08%)
BABA   252.10 (-5.11%)
TSLA   1,452.71 (-2.48%)
MU   48.75 (+0.10%)
GE   6.40 (+1.11%)
AMD   84.85 (-2.15%)
T   30.02 (+0.60%)
F   6.86 (-1.01%)
ACB   10.27 (-0.39%)
GILD   69.35 (+0.78%)
NFLX   494.73 (-2.82%)
DIS   129.93 (-0.68%)
BAC   26.11 (+2.51%)
BA   170.02 (-1.27%)
S&P 500   3,351.28 (+0.06%)
DOW   27,433.48 (+0.17%)
QQQ   271.47 (-1.15%)
AAPL   444.45 (-2.45%)
MSFT   212.48 (-1.79%)
FB   268.44 (+1.19%)
GOOGL   1,498.37 (-0.44%)
AMZN   3,167.46 (-1.78%)
NVDA   447.98 (-1.20%)
CGC   16.63 (-5.08%)
BABA   252.10 (-5.11%)
TSLA   1,452.71 (-2.48%)
MU   48.75 (+0.10%)
GE   6.40 (+1.11%)
AMD   84.85 (-2.15%)
T   30.02 (+0.60%)
F   6.86 (-1.01%)
ACB   10.27 (-0.39%)
GILD   69.35 (+0.78%)
NFLX   494.73 (-2.82%)
DIS   129.93 (-0.68%)
BAC   26.11 (+2.51%)
BA   170.02 (-1.27%)
S&P 500   3,351.28 (+0.06%)
DOW   27,433.48 (+0.17%)
QQQ   271.47 (-1.15%)
AAPL   444.45 (-2.45%)
MSFT   212.48 (-1.79%)
FB   268.44 (+1.19%)
GOOGL   1,498.37 (-0.44%)
AMZN   3,167.46 (-1.78%)
NVDA   447.98 (-1.20%)
CGC   16.63 (-5.08%)
BABA   252.10 (-5.11%)
TSLA   1,452.71 (-2.48%)
MU   48.75 (+0.10%)
GE   6.40 (+1.11%)
AMD   84.85 (-2.15%)
T   30.02 (+0.60%)
F   6.86 (-1.01%)
ACB   10.27 (-0.39%)
GILD   69.35 (+0.78%)
NFLX   494.73 (-2.82%)
DIS   129.93 (-0.68%)
BAC   26.11 (+2.51%)
BA   170.02 (-1.27%)
S&P 500   3,351.28 (+0.06%)
DOW   27,433.48 (+0.17%)
QQQ   271.47 (-1.15%)
AAPL   444.45 (-2.45%)
MSFT   212.48 (-1.79%)
FB   268.44 (+1.19%)
GOOGL   1,498.37 (-0.44%)
AMZN   3,167.46 (-1.78%)
NVDA   447.98 (-1.20%)
CGC   16.63 (-5.08%)
BABA   252.10 (-5.11%)
TSLA   1,452.71 (-2.48%)
MU   48.75 (+0.10%)
GE   6.40 (+1.11%)
AMD   84.85 (-2.15%)
T   30.02 (+0.60%)
F   6.86 (-1.01%)
ACB   10.27 (-0.39%)
GILD   69.35 (+0.78%)
NFLX   494.73 (-2.82%)
DIS   129.93 (-0.68%)
BAC   26.11 (+2.51%)
BA   170.02 (-1.27%)
Log in

NASDAQ:FLGTFulgent Genetics Stock Price, Forecast & News

$35.84
-0.81 (-2.21 %)
(As of 08/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$35.39
Now: $35.84
$38.70
50-Day Range
$15.73
MA: $20.30
$36.65
52-Week Range
$6.70
Now: $35.84
$43.64
Volume494,236 shs
Average Volume417,360 shs
Market Capitalization$781.67 million
P/E Ratio298.69
Dividend YieldN/A
Beta1.93
Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, learning software, and genetic diagnostics tools and integrated laboratory processes. The company primarily serves hospitals and medical institutions. It markets its tests through internal sales force, as well as through independent sales representatives in the United States, Canada, the People's Republic of China, and internationally. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.
Read More
Fulgent Genetics logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.3Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.50 out of 5 stars


Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FLGT
CUSIPN/A
Phone626-350-0537

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$32.53 million
Cash Flow$0.14 per share
Book Value$4.42 per share

Profitability

Net Income$-410,000.00

Miscellaneous

Employees123
Market Cap$781.67 million
Next Earnings Date11/2/2020 (Estimated)
OptionableNot Optionable
$35.84
-0.81 (-2.21 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive FLGT News and Ratings via Email

Sign-up to receive the latest news and ratings for FLGT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Fulgent Genetics (NASDAQ:FLGT) Frequently Asked Questions

How has Fulgent Genetics' stock been impacted by COVID-19 (Coronavirus)?

Fulgent Genetics' stock was trading at $10.06 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, FLGT shares have increased by 256.3% and is now trading at $35.84.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Fulgent Genetics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fulgent Genetics in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Fulgent Genetics
.

When is Fulgent Genetics' next earnings date?

Fulgent Genetics is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020.
View our earnings forecast for Fulgent Genetics
.

How were Fulgent Genetics' earnings last quarter?

Fulgent Genetics Inc (NASDAQ:FLGT) issued its quarterly earnings data on Tuesday, August, 4th. The company reported $0.17 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.01 by $0.16. Fulgent Genetics had a net margin of 5.78% and a return on equity of 5.30%.
View Fulgent Genetics' earnings history
.

What price target have analysts set for FLGT?

5 brokerages have issued 12 month price objectives for Fulgent Genetics' stock. Their forecasts range from $11.00 to $68.00. On average, they anticipate Fulgent Genetics' stock price to reach $24.46 in the next year. This suggests that the stock has a possible downside of 31.8%.
View analysts' price targets for Fulgent Genetics
.

Has Fulgent Genetics been receiving favorable news coverage?

News coverage about FLGT stock has trended very positive this week, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Fulgent Genetics earned a news sentiment score of 4.0 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days.
View the latest news about Fulgent Genetics
.

Are investors shorting Fulgent Genetics?

Fulgent Genetics saw a increase in short interest during the month of July. As of July 31st, there was short interest totaling 1,010,000 shares, an increase of 8.5% from the July 15th total of 931,200 shares. Based on an average daily trading volume, of 468,200 shares, the days-to-cover ratio is currently 2.2 days. Approximately 9.1% of the company's shares are sold short.
View Fulgent Genetics' Current Options Chain
.

Who are some of Fulgent Genetics' key competitors?

What other stocks do shareholders of Fulgent Genetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fulgent Genetics investors own include Crispr Therapeutics (CRSP), NVIDIA (NVDA), Inseego (INSG), InVitae (NVTA), Marvell Technology Group (MRVL), NeoGenomics (NEO), Alibaba Group (BABA), Baidu (BIDU), Editas Medicine (EDIT) and Bilibili (BILI).

Who are Fulgent Genetics' key executives?

Fulgent Genetics' management team includes the following people:
  • Mr. Ming Hsieh, Chairman, CEO & Pres (Age 63)
  • Mr. Paul Kim, Chief Financial Officer (Age 52)
  • Dr. Han Lin Gao, Chief Scientific Officer & Lab Director (Age 52)

When did Fulgent Genetics IPO?

(FLGT) raised $60 million in an initial public offering on Thursday, September 29th 2016. The company issued 4,600,000 shares at $12.00-$14.00 per share. Credit Suisse and Piper Jaffray acted as the underwriters for the IPO and Raymond James and BTIG were co-managers.

What is Fulgent Genetics' stock symbol?

Fulgent Genetics trades on the NASDAQ under the ticker symbol "FLGT."

Who are Fulgent Genetics' major shareholders?

Fulgent Genetics' stock is owned by many different institutional and retail investors. Top institutional investors include Raymond James Trust N.A. (3.63%), Russell Investments Group Ltd. (2.19%), Essex Investment Management Co. LLC (0.76%), Cadence Capital Management LLC (0.35%), New York State Common Retirement Fund (0.18%) and Raymond James Financial Services Advisors Inc. (0.17%). Company insiders that own Fulgent Genetics stock include Jian Xie, John C Bolger, Ming Hsieh and Paul Kim.
View institutional ownership trends for Fulgent Genetics
.

Which major investors are selling Fulgent Genetics stock?

FLGT stock was sold by a variety of institutional investors in the last quarter, including Cadence Capital Management LLC, Mutual Advisors LLC, Cornerstone Investment Partners LLC, and Essex Investment Management Co. LLC. Company insiders that have sold Fulgent Genetics company stock in the last year include Jian Xie, John C Bolger, and Paul Kim.
View insider buying and selling activity for Fulgent Genetics
.

Which major investors are buying Fulgent Genetics stock?

FLGT stock was purchased by a variety of institutional investors in the last quarter, including Raymond James Trust N.A., Russell Investments Group Ltd., Raymond James Financial Services Advisors Inc., Virtu Financial LLC, Principal Financial Group Inc., Juncture Wealth Strategies LLC, New York State Common Retirement Fund, and UBS Group AG.
View insider buying and selling activity for Fulgent Genetics
.

How do I buy shares of Fulgent Genetics?

Shares of FLGT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Fulgent Genetics' stock price today?

One share of FLGT stock can currently be purchased for approximately $35.84.

How big of a company is Fulgent Genetics?

Fulgent Genetics has a market capitalization of $781.67 million and generates $32.53 million in revenue each year. The company earns $-410,000.00 in net income (profit) each year or $0.02 on an earnings per share basis. Fulgent Genetics employs 123 workers across the globe.

What is Fulgent Genetics' official website?

The official website for Fulgent Genetics is www.fulgentgenetics.com.

How can I contact Fulgent Genetics?

Fulgent Genetics' mailing address is 4978 SANTA ANITA AVENUE SUITE 205, TEMPLE CITY CA, 91780. The company can be reached via phone at 626-350-0537 or via email at [email protected]

This page was last updated on 8/7/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.